DNA repair defect other than combined T-cell and B-cell immunodeficiencies

DNA repair defect other than combined T-cell and B-cell immunodeficiencies (Orphanet code 169346) is a grouping category within the Orphanet classification that encompasses a set of rare genetic disorders characterized by defects in DNA damage recognition, signaling, or repair pathways that lead to immunodeficiency predominantly affecting either cellular or humoral immunity, but not presenting as a classical combined T-cell and B-cell immunodeficiency. These conditions are distinct from the more well-known combined immunodeficiencies (such as those seen in severe combined immunodeficiency or ataxia-telangiectasia) in that the immune defect may be more selective or may manifest alongside other systemic features related to impaired DNA repair, including increased sensitivity to ionizing radiation or certain chemicals, chromosomal instability, and a predisposition to malignancy. Patients in this category may present with recurrent infections due to impaired immune function, growth retardation, developmental abnormalities, and an elevated risk of cancer, particularly lymphoid malignancies. Neurological involvement, skin abnormalities, and bone marrow failure may also be observed depending on the specific underlying genetic defect. The body systems most commonly affected include the immune system, the hematopoietic system, the nervous system, and the skin. Because this is a classification grouping rather than a single disease entity, the clinical presentation varies considerably depending on the specific gene involved and the nature of the DNA repair pathway affected. Treatment is largely supportive and depends on the specific condition within this group. Management may include immunoglobulin replacement therapy for antibody deficiency, prophylactic antibiotics and antifungals, hematopoietic stem cell transplantation in severe cases, and cancer surveillance protocols. Avoidance of unnecessary radiation exposure is important in conditions with radiosensitivity. Gene-specific therapies are under investigation but are not yet widely available. A multidisciplinary approach involving immunologists, hematologists, oncologists, and geneticists is essential for optimal care.

Common questions about DNA repair defect other than combined T-cell and B-cell immunodeficiencies